Physician profile
Ann B May
NPI 1740284116
$991.09
in general payments reported to CMS, 2019-2025
14 companies · $90.62 in 2025
The $90.62 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $165 · 2022: $289 · 2023: $268 · 2024: $178 · 2025: $90.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $537.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $191.52 | 2021-2024 | |
| Novo Nordisk INC | $144.48 | 2021-2023 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $136.46 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $114.46 | 2022-2024 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $105.69 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $66.60 | 2024 | |
| Supernus Pharmaceuticals, INC. | $58.18 | 2024-2025 | Qelbree |
| Collegium Pharmaceutical, INC. | $56.85 | 2025 | Jornay Pm |
| Lilly USA, LLC | $31.48 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $20.83 | 2022 | |
| Astellas Pharma US INC | $19.34 | 2023 | Veozah |
| Merck Sharp & Dohme LLC | $18.55 | 2025 | Vaxelis, M-M-R II, Gardasil 9 |
| Sanofi Pasteur INC. | $13.56 | 2022 | |
| Lundbeck LLC | $13.09 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.